Skip to main content
Journal cover image

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Publication ,  Conference
Rizzieri, DA; Schiller, GJ; Solomon, SR; Newell, LF; Erba, HP; Ryan, RJ; Faderl, S; Cortes, JE; Lancet, JE
Published in: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
March 1, 2020

Duke Scholars

Published In

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

EISSN

1523-6536

ISSN

1083-8791

Publication Date

March 1, 2020

Volume

26

Issue

3

Start / End Page

S105 / S106

Location

Orlando, FL

Publisher

ELSEVIER SCIENCE INC

Conference Name

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR

Related Subject Headings

  • Immunology
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rizzieri, D. A., Schiller, G. J., Solomon, S. R., Newell, L. F., Erba, H. P., Ryan, R. J., … Lancet, J. E. (2020). Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis. In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (Vol. 26, pp. S105–S106). Orlando, FL: ELSEVIER SCIENCE INC.
Rizzieri, David A., Gary J. Schiller, Scott R. Solomon, Laura F. Newell, Harry P. Erba, Robert J. Ryan, Stefan Faderl, Jorge E. Cortes, and Jeffrey E. Lancet. “Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis.” In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 26:S105–6. ELSEVIER SCIENCE INC, 2020.
Rizzieri DA, Schiller GJ, Solomon SR, Newell LF, Erba HP, Ryan RJ, et al. Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis. In: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC; 2020. p. S105–6.
Rizzieri, David A., et al. “Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis.” BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol. 26, no. 3, ELSEVIER SCIENCE INC, 2020, pp. S105–06.
Rizzieri DA, Schiller GJ, Solomon SR, Newell LF, Erba HP, Ryan RJ, Faderl S, Cortes JE, Lancet JE. Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC; 2020. p. S105–S106.
Journal cover image

Published In

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

EISSN

1523-6536

ISSN

1083-8791

Publication Date

March 1, 2020

Volume

26

Issue

3

Start / End Page

S105 / S106

Location

Orlando, FL

Publisher

ELSEVIER SCIENCE INC

Conference Name

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR

Related Subject Headings

  • Immunology
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences